SMAD2 and neoplasm: Further, immunohistochemical (IHC) analysis of tumor tissues confirmed that the combination of α-hederin and PTX significantly decreased the expression of SREBF1, FASN, phosphorylated SMAD2, and the sEVs-marker protein TSG101 compared to PTX alone.